Search This Blog

Friday, August 2, 2024

UK PM Calls For Crackdown On Angry Brits - Violent Migrants Get Pass

 Beyond the obvious Cloward-Piven agenda in play throughout most of Europe and the US, open border policies accomplish much more than simply erasing western culture with third-world migrants.  The introduction of violent peoples from violent countries and ideologies is a perfect way to generate public hostility and getting them to react in anger.  When a government refuses to represent the interests of actual citizens that are under attack by foreign elements the only avenue left to that populace is self defense.

Establishment elites understand very well that their malicious activities are going to generate a vengeful response.  Their first measure is to shame the public with accusations of "extremism" when the public fights back.  When that doesn't work, the next measure is to use popular riots as an excuse to impose authoritarian controls "in the name of safety."

In other words, government officials invite brutal people into the society, let those people run amok while refusing to protect the public, then those same officials punish the public for protecting themselves after leaving them no other choice.

This Hegelian Dialectic is ever present today in the UK where a teenage child of Rwandan migrants planned and executed a violent knife attack on a community center hosting a children's dance recital.  Three young girls are now dead and at least ten others were injured.  The UK media has attempted to spin the event as if it is rooted in mental illness (the attack was planned - not spontaneous).  They lied by omission when they initially tried to hide the family origins of the attacker.  And, they have chastised Brits who rightly took to the streets to protest across the country.

This is not only about one knife attack in the community of Southport, it's about thousands upon thousands of incidents spanning many years of migrant criminality and the government manipulation of statistics to hide the growing problem.  An examination of violent crime rates in England and Wales shows an explosion of incidents from 2014 onward; right after open refugee and asylum standards were implemented across the EU (including the UK at that time) to increase migrants from the Middle East and Africa.

UK police and political authorities specifically avoid keeping a record of the migrant status of most perpetrators, making it difficult to directly prove who is responsible for the crime spike.  Correlation is not necessarily causation, but there were no other dramatic changes to UK society during that time period that would account for the crime spike.  The only thing that changed was the type of migrants the UK government was accepting and the amount of people they were allowing in.

Remove the migrants and watch crime numbers plummet; it's that simple.  The UK public knows it and those in power choose to ignore it.  This has led to predictable conflict.  

The level of gaslighting used to counter rising discontent in the UK is rather familiar to many conservatives in the US.  Whenever patriots take any form of action, the propaganda is swift and officials automatically demand greater powers to "stop extremism."  UK Prime Minister Sir Keir Starmer has announced a plan to crack down, not on violent migrants, but on protesting Brits.  

"These thugs are mobile,"Starmer claims, "they move from community to community. We must have a policing response that can do the same."

His warnings also included a message to social media companies to stop protest rhetoric on their websites, an obvious hint that the UK will be seeking internet censorship as a way to stop inconvenient information from spreading. 

Was this the plan all along?  The government apathy to the migrant flood makes perfect sense when you consider the concept of Problem, Reaction, Solution.

Keep in mind, leftist protests and riots have been ongoing in the UK for the past year in the name of Gaza, among other causes.  The law enforcement response to these situations has been minimal.  It is clear that there is a grotesque double standard when it comes to conservative or nationalist protests - If you aren't on Team Progressive, then you aren't allowed a redress of grievances.  The left is allowed to riot, conservatives are not even allowed to take to the streets.  This is what happened after January 6th in the US and it's happening right now in the UK.

If the goal is a dystopian nightmare state then the UK is well on its way.  The public has made clear that they will no longer be abused.  The question is, who will blink first - The populace under threat of Orwellian surveillance and lockdowns, or the establishment fearing that the civil unrest they so hoped to trigger might grow out of their control.  

https://www.zerohedge.com/political/uk-prime-minister-calls-crackdown-angry-brits-violent-migrants-get-pass

Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest

 The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data presented at an Alzheimer's meeting on Tuesday.

In the companies' pivotal clinical trial, Leqembi reduced cognitive decline by 27% after 18 months - data that supported the drug's approval last year.

The new study looked at how the drug performed in about 95% of trial patients who continued on the treatment. After three years, Leqembi slowed cognitive decline by 31% compared to what would be expected in similar patients who did not receive treatment.

There were no new safety findings over the three-year period. Brain swelling and bleeding associated with drugs that work by removing amyloid plaque from the brain largely occurred within the first six months of treatment, Dr. Christopher van Dyck, director of the Yale's Alzheimer's Disease Research Unit, told the meeting.

A separate analysis of data from a midstage study looked at patients who had a gap in treatment of 9 to 59 months following 18 months of initial treatment. In that study, there was still a difference, but once treatment stopped, the rate of cognitive decline reverted back to what was seen in patients on placebo.

Discontinuation of treatment also showed increases in Alzheimer's-related disease biomarkers, such as the return of amyloid plaques.

The findings were part of several presentations at the Alzheimer's Association International Conference in Philadelphia aimed at showing that Eisai's drug continues to benefit patients who stay on Leqembi after amyloid has been removed.

Eisai's drug targets protofibrils - toxic building blocks that eventually form clumps in the brain known as amyloid plaques, a hallmark of Alzheimer's disease. Leqembi both removes amyloid plaques and continues to target protofibrils, which can injure brain cells.

"There is no question long-term benefit is better than short-term benefit," Dr. Lynn Kramer, Eisai's chief clinical officer, told Reuters.

The studies underline differences between Eisai and Biogen's treatment and Eli Lilly's Alzheimer's drug Kisunla (donanemab), which was approved on July 2.

The Lilly drug exclusively targets amyloid plaques. Once the brain plaque is gone, patients can discontinue treatment.

https://www.yahoo.com/news/benefit-eisai-biogens-alzheimers-drug-223918847.html

Biogen lifts profit forecast, signals progress in turnaround effort

 Biogen lifted its full-year profit forecast on Thursday due to cost cuts and better-than-expected sales of its various treatments, even as the U.S. adoption of its Alzheimer's drug remains slow.

CEO Christopher Viehbacher, who is spearheading a turnaround at Biogen since taking over the top job in 2022, said the company was now positioned for growth after a series of cost-cutting efforts, multiple acquisitions and a narrowed focus on new launches.

"We're not done yet, and we've certainly had a few setbacks along the way. But I think we can now focus on sustainable growth," Viehbacher told reporters.

Biogen also beat estimates for profit in the second quarter, helped by better-than-expected performance of its newer drugs such as rare disease treatment Skyclarys as well as older multiple sclerosis treatments.

Sales of Alzheimer's drug Leqembi, which it sells with Japan's Eisai, came in at $40 million, modestly above estimates of $32 million.

Its take-up has been slow due to requirements such as additional diagnostic tests, twice-monthly infusions and regular brain scans, and its EU application was rejected last week.

The company also said it had decided to retain its biosimilars business after a year-long review.

In the second quarter, sales of older multiple sclerosis drug, which are facing competition from rivals, fell 4.9% to $1.15 billion but came in ahead of estimates of $1.4 billion.

Skyclarys brought in sales of $100 million for the quarter. Analysts had expected $92.06 million.

The drugmaker raised its 2024 adjusted per-share profit forecast to a range of $15.75 to $16.25 from $15 to $16 previously. The company's second-quarter adjusted profit of $5.28 per share beat estimates of $4.03.

Shares of the company were marginally higher at $214.44 in premarket trading.

This is overall a decent quarter, said Jefferies analyst Michael Yee, but said there was "no major thesis change".

https://finance.yahoo.com/news/biogen-lifts-2024-profit-forecast-105037122.html

Countries Using The Most Energy Per Capita

 Global energy consumption has significant regional variations due to differences in industrialization levels, climate conditions, population density, and access to natural resources, as well as varying energy policies and economic activities across countries.

For instance, countries with colder climates may consume more energy for heating, while highly industrialized nations may have higher per capita energy usage due to their extensive manufacturing sectors.

This chart below, via Visual Capitalist's Kayla Zhu, shows the top 15 countries by energy consumption per capita in 2023, as well as the consumption per capita for each global region.

The figures are represented in gigajoules (GJ) per capita and come from the Energy Institute’s Statistical Review of World Energy 2024 report.

Qatar and Iceland Consume Most Energy Per Capita

Qatar had the highest per capita energy consumption worldwide in 2023 at 817 GJ per person. Almost all of the country’s energy consumption is derived from natural gas, of which the country has abundant reserves.

Countries located in hot or cold climates that are also rich in a particular energy resource, such as Qatar and its natural gas or Iceland and its geothermal energy, made up many of the top per capita energy consumers in 2023.

These countries tend to consume more energy to heat or cool homes and often use more energy since electricity costs are often on the lower end. Along with this, many of the top energy consuming countries per capita have fairly low populations, with Canada and Saudi Arabia being the only nations in the top 10 with populations of more than 10 million.

A Regional Perspective

Looking at global regions, North America unsurprisingly consumes the most energy per person, at 240 GJ per capita, almost three times the global average of 77 GJ.

North America’s numbers are in contrast to regions like Africa, that consumes 14 GJ per capita, or even South and Central America at 58 GJ per capita.

According to the Energy Institute, around 750 million people worldwide, or 1 out of every 10 people do not have access to electricity.

https://www.zerohedge.com/energy/these-countries-are-using-most-energy-capita

Thursday, August 1, 2024

Ultragenyx Results and Corporate Update

 Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million

Increased 2024 expected total revenue guidance to $530 million to $550 million

https://www.biospace.com/ultragenyx-reports-second-quarter-2024-financial-results-and-corporate-update

INmune results, update

 Financial Results for the First Quarter Ended June 30, 2024:

  • Net loss attributable to common stockholders for the quarter ended June 30, 2024 was approximately $9.7 million, compared to approximately $6.5 million during the quarter ended June 30, 2023.
  • Research and development expenses totaled approximately $7.1 million for the quarter ended June 30, 2024, compared to approximately $4.1 million during the quarter ended June 30, 2023.
  • General and administrative expenses were approximately $2.8 million for the quarter ended June 30, 2024, compared to approximately $2.3 million during the quarter ended June 30, 2023.
  • Other income (expense), net was approximately $0.1 million for the quarter ended June 30, 2024, compared to approximately ($0.1) million during the quarter ended June 30, 2023.
  • As of June 30, 2024, the Company had cash and cash equivalents of approximately $31.1 million.
  • As of August 1, 2024, the Company had approximately 19.8 million common shares outstanding.

Earnings Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.

Date: August 1, 2024
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-225-9448
Participant Dial-in (international): 1-203-518-9708
Conference ID: INMUNE

A live audio webcast of the call can be accessed by clicking here or using this link:
https://viavid.webcasts.com/starthere.jsp?ei=1679432&tp_key=8a15b560a4

A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 8, 2024, by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11156467.

https://www.biospace.com/inmune-bio-inc-announces-second-quarter-2024-results-and-provides-business-update

Stock Slump Deepens as Japan Falls Most Since 2020

 

  • Treasuries extend rally with 2-year yields declining on Friday
  • Economists expect BOJ to hike again by end of the year

Japanese stocks plunged for a second day on expectations for further monetary tightening in the country, exacerbating a global selloff following weak US economic data and tech earnings.

The Topix index fell as much as 5.7%, the most since 2020, as the yen traded near its strongest since March to weigh on Japan’s export-oriented economy. Shares also dropped across Asia from South Korea to Hong Kong, with AI chipmaker SK Hynix Inc. tumbling 8.7%.

https://www.bloomberg.com/news/articles/2024-08-01/stock-market-today-dow-s-p-live-updates